The University of California San Diego School of Medicine is the graduate medical school of the University of California, San Diego. It was the third medical school in the University of California system, after those established at UCSF and UCLA, and is the only medical school in the San Diego metropolitan area.

During the past decade, University of California, San Diego, School of Medicine conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 3 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of California, San Diego, School of Medicine" #1 sponsor was "University of California, San Diego" with 4 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Celgene" with 1 trials sponsored, "Columbia University" with 1 trials sponsored and "Eisai Inc." with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of California, San Diego, School of Medicine" #1 collaborator was "Pamlab, L.L.C." with 2 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Michael J. Fox Foundation for Parkinson's Research" with 1 trials as a collaborator and "National Institute on Drug Abuse (NIDA)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "University of California, San Diego, School of Medicine" are "Autism Spectrum Disorders" (1 trials), "B-cell Lymphoma" (1 trials), "Carcinoma, Hepatocellular" (1 trials), "Coronary Artery Disease" (1 trials) and "Cystinosis" (1 trials). Many other conditions were trialed in "University of California, San Diego, School of Medicine" in a lesser frequency.

Most popular intervention types in "University of California, San Diego, School of Medicine" are "Drug" (10 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Bevacizumab" (2 trials), "2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)" (1 trials), "6(S)-5-MTHF (a Medical Food)" (1 trials) and "6(S)-5-MTHF(Deplin)" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of California, San Diego, School of Medicine" are 12 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University of California, San Diego, School of Medicine". 1 are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in University of California, San Diego, School of Medicine, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in University of California, San Diego, School of Medicine, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".